Cardiff Oncology Inc
CRDF
Company Profile
Business description
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
Contact
11055 Flintkote Avenue
San DiegoCA92121
USAT: +1 858 952-7570
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
33
Stocks News & Analysis
stocks
Market too pessimistic about unloved ASX health care share
Our analysts believe a long-term margin recovery is underway.
stocks
Two overvalued ASX shares to avoid
Both shares trade at a significant premium to our fair value.
stocks
Materially undervalued ASX tech share
Long reinvestment runway supports our thesis on ASX technology company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,905.70 | 0.10 | -0.00% |
| CAC 40 | 7,959.67 | 21.40 | -0.27% |
| DAX 40 | 23,464.63 | 225.45 | 0.97% |
| Dow JONES (US) | 47,112.45 | 867.04 | 1.87% |
| FTSE 100 | 9,548.03 | 8.32 | 0.09% |
| HKSE | 25,995.50 | 100.95 | 0.39% |
| NASDAQ | 23,025.59 | 752.51 | 3.38% |
| Nikkei 225 | 49,646.24 | 986.72 | 2.03% |
| NZX 50 Index | 13,582.31 | 101.88 | 0.76% |
| S&P 500 | 6,765.88 | 60.76 | 0.91% |
| S&P/ASX 200 | 8,614.70 | 1.30 | -0.02% |
| SSE Composite Index | 3,875.48 | 5.45 | 0.14% |